Galectin Therapeutics (GALT) Net Cash Flow (2010 - 2026)

Galectin Therapeutics' Net Cash Flow history runs 17 years deep, the most recent figure standing at -$3.6 million for Q1 2026.

• On a quarterly basis, Net Cash Flow rose 53.06% year-over-year to -$3.6 million in Q1 2026; TTM through Mar 2026 was $6.7 million, a 141.26% increase from a year earlier, with the FY2025 full-year figure at $2.6 million, up 124.43% from the prior year.
• Net Cash Flow eased to -$3.6 million in Q1 2026 per GALT's latest filing, from $6.1 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $6.3 million in Q2 2025 and bottomed at -$11.9 million in Q4 2024.
• The 5-year median for Net Cash Flow is -$793000.0 (2023), against an average of -$1.5 million.
• Biggest YoY gain for Net Cash Flow was 1143.11% in 2024; the steepest drop was 326.87% in 2024.
• Year by year, Net Cash Flow stood at $2.8 million in 2022, then soared by 90.62% to $5.3 million in 2023, then sank by 326.87% to -$11.9 million in 2024, then soared by 151.4% to $6.1 million in 2025, then sank by 158.81% to -$3.6 million in 2026.
• Per Business Quant, the three latest GALT Net Cash Flow figures stand at -$3.6 million (Q1 2026), $6.1 million (Q4 2025), and -$2.2 million (Q3 2025).